Australia and New Zealand have adopted improved sunscreen quality, safety and efficacy legislation taking effect from 1 July 2024. bit.ly/3UgT57Z
AMLo Biosciences hope that other countries will follow suit to help reduce the incidence of #melanoma and #skincancer .

We were interested to read a Norwegian study looking at the incidence and factors that accompany second primary invasive #melanoma . Retrospective data revealed that older age and male sex were associated with an increased risk of a second primary tumour. bit.ly/43XdbaG

We are delighted that our Chief Marketing Officer has been voted onto the British In Vitro Diagnostics Association (BIVDA) board. “It’s vital that the NHS and others are aware of forthcoming innovative products that can help diagnose, prevent and treat a range of medical conditions,” said Jane Meaney

Patients prefer augmented intelligence with 3D total-body photography for #melanoma recognition rather than #dermatologist exam alone. Dermatologists continue to rely on their own decision making despite having a high level of confidence in AI-results. bit.ly/43HW6Bb

AMLo Biosciences fully agree that sunbathing and tanning carries such high risk of #skincancer and #melanoma that it is best to avoid. Seek shade, cover up and enjoy the sunshine safely.

US military veterans (especially Air Force veterans) are at high risk of #melanoma . This is due to service in countries close to the equator where UV levels are higher and to lack of access to sun protection during active service. bit.ly/49wTHLf

A US study shows an increase in immunohistochemistry to help decision making in #melanoma patients aged 65+. bit.ly/43EpVmq
We believe IHC can provide prognostic information to help avoid invasive diagnostic procedures, lengthy follow-up, or unnecessary treatment.

Age-related changes in the skin may also contribute to higher rates of metastatic #melanoma in older people. Research shows that increased generation of blood vessels in tumours and vessel leakage allows tumour cells to escape and spread. bit.ly/3vAa4sz

The official Medilink North Healthcare Business award photos are in! AMLo Biosciences and Newcastle University are proud of winning the Partnership with Academia section for our suite of prognostic products for patients with early-stage #melanoma .

Calling all dermatologists, histologists and pathologists at #EADO2024 !
Today is the last chance to test your knowledge of harmless moles, potential melanomas, and other skin lesions with our interactive #dermatology quiz.
Visit AMLo Biosciences booth 27!
#melanoma

AMLo Biosciences want to highlight two key posters being presented at #EADO2024 today!
P-140: biomarker use to identify benign and borderline pigmented lesions
P-XXX: biomarkers use to risk stratify patients with early-stage melanomas

Can you identify a #melanoma from naevus?
AMLo Biosciences are offering their interactive #dermatology quiz at #EADO2024 in Paris: booth 27. Please visit to test your diagnostic knowledge.
bit.ly/3xlZd5Z

AMLo Biosciences are delighted to be attending European Association of Dermato-Oncology Congress, Paris 4-6 April. #EADO2024
Stop by booth 27 to speak to the team, take our interactive #dermatology quiz and find out about #AMBLor our prognostic technology. bit.ly/3xlZd5Z

Happy Easter weekend from all at AMLo Biosciences

AMLo Biosciences fully support this message from IMPACT Melanoma and want to extend the warning about using tanning booths. Sun damage to the skin from indoor or outdoor exposure dramatically increases the risk of #melanoma . Be #skinaware .

Recent survey data in JAMA Dermatology revealed that early-stage melanoma patients, despite excellent prognoses, had intense negative psychological experiences. bit.ly/3T8beTS.
#AMBLor can provide reassurance to those found to be at low risk of disease progression.

AMLo Biosciences and @NewcastleUniversity are delighted to win the Medilink North 'Collaboration with Academia” Healthcare Business Award last night for the development of #AMBLor and our research into improving #melanoma management.

AMLo Biosciences are taking part in the North East Life Science Conference today at the Catalyst, Newcastle, UK. Come and talk to us about our prognostic technology #AMBLor that identifies low-risk melanomas and our research into other skin cancers. #NELifeSci24 #melanoma

AMLo Biosciences are attending the Scottish Skin Cancer Annual Meeting, 21 March, in Dunblane that brings together 3 cancer networks. We are looking forward to speaking to experts about how our prognostic #AMBLor technology could aid #melanoma clinical decision making.

AMLo Biosciences want to highlight a recent publication with @Penny_Lovat as an author. This paper reports a proof-of-concept study for biomarkers AMBRA1 and SQSTM1 in the identification of cutaneous squamous cell carcinomas at high risk of metastasis. tinyurl.com/amlo-cscc